AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
6,390.00
-12.00 (-0.19%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close6,402.00
Open6,420.00
Bid6,376.00 x 0
Ask6,378.00 x 0
Day's Range6,359.00 - 6,454.00
52 Week Range5,312.00 - 6,634.00
Volume1,610,130
Avg. Volume2,085,668
Market Cap83.823B
Beta (3Y Monthly)1.10
PE Ratio (TTM)33.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.15 (3.36%)
Ex-Dividend Date2019-02-28
1y Target EstN/A
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 27-Jan-11 12:00pm GMT

    Q4 & Full Year 2010 AstraZeneca PLC Earnings Conference Call

  • Financial Times4 days ago

    AstraZeneca to pay millions of pounds to former staff

    AstraZeneca has moved to end a dispute with workers at a site it formerly owned by agreeing to earmark millions of pounds to cover severance pay after the new owners closed the facility. The row, first disclosed by The Times, centred on Astra’s decision to sell the manufacturing site in Avonmouth, Bristol — known as Avlon — to the pharma company Avara for £1 at the end of 2016. Avara fell into administration earlier this year.

  • Reuters5 days ago

    FOCUS-As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

    For much of its 141-year history, Japan's Shionogi & Co Ltd has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force. It followed that pattern for blockbuster cholesterol treatment Crestor, its biggest success story, which was developed in-house until mid-stage trials when it teamed up with AstraZeneca Plc. AstraZeneca gained the rights to sell the drug in all markets but Japan.

  • Philadelphia cell therapy startup adds Big Pharma veteran to its team
    American City Business Journals5 days ago

    Philadelphia cell therapy startup adds Big Pharma veteran to its team

    The Philadelphia company's new chief medical officer has spent time with several Big Pharma companies with ties to the region.

  • AI Drug Hunters Could Give Big Pharma a Run for Its Money
    Bloomberg6 days ago

    AI Drug Hunters Could Give Big Pharma a Run for Its Money

    (Bloomberg) -- Machine-learning technology has beaten humans at games of chess and Go to worldwide fanfare. A demonstration of its eerily lifelike prowess in making phone calls to unsuspecting people went viral.But a less-noticed win for DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., at a biennial biology conference could upend how drugmakers find and develop new medicines. It could also dial up pressure on the world’s largest pharmaceutical companies to prepare for a technological arms race. Already, a new breed of upstarts are jumping into the fray.In December, at the CASP13 meeting in Riviera Maya, Mexico, DeepMind beat seasoned biologists at predicting the shapes of proteins, the basic building blocks of disease. The seemingly esoteric pursuit has serious implications: A tool that can accurately model protein structures could speed up the development of new drugs. “Absolutely stunning,” tweeted one scientist after the raw results were posted online. “It was a total surprise,” said conference founder John Moult, a University of Maryland computational biologist. “Compared to the history of what we had been able to do, it was pretty spectacular.” Sorting out the structure of proteins in order to find ways for medicines to attack disease is an enormously complex problem. Researchers still don’t fully understand the rules for how proteins are built. And then there’s the math: There are more possible protein shapes than there are atoms in the universe, making prediction a herculean undertaking of computation. For a quarter century, computational biologists have labored to devise software equal to the task.Enter DeepMind. With limited experience in protein folding — the physical process by which a protein acquires its three-dimensional shape — but armed with the latest neural-network algorithms, DeepMind did more than what 50 top labs from around the world could accomplish. Excitement rippled around the Mayan-themed resort where the meeting was held. Two DeepMind presenters were peppered with questions from scientists about how they had done it. Within hours, the British newspaper The Guardian said DeepMind’s AI could “usher in new era of medical progress.”  In a blog post, the company bragged that its protein models were “far more accurate than any that have come before,” opening up “new potential within drug discovery.”In an email, DeepMind said its scientists were “fully focused on their research” and not available for interviews. DeepMind’s simulation doesn’t yet produce the kind of atomic-level resolution that is important for drug discovery. And though many companies are looking for ways to use computers to identify new medications, few machine-learning-based drugs have progressed to the point of being tested in humans. It will be years before anyone knows whether such software can regularly spot promising therapies that researchers might otherwise have missed.Artificial intelligence is a chic catchphrase in health care, often trotted out as a cure-all for whatever ails the industry. It has been held up as a potential solution to fix cumbersome electronic medical records, speed up diagnosis and make surgery more precise. DeepMind’s victory points to a possible practical application for the technology in one of the most expensive and failure-prone parts of the pharmaceutical business. Some observers said that the fact that a team of outsiders could make such significant progress in untangling one of the most vexing problems of biology is a black eye for researchers in the field. It could also be a portent for the drug industry, which spends billions on research and development, but was beaten to the punch.  Mohammed AlQuraishi, a Harvard computational biology researcher who attended the conference, wrote in a blog post that giant pharmaceutical companies haven’t put a serious effort into protein folding, essentially ceding the ground to tech companies. While drug companies dithered, “Alphabet swoops in and sets up camp right in their backyard,” he wrote.Finding new drugs and bringing them to market is notoriously difficult. According to some estimates, big drugmakers spend more than $2.5 billion to get a new medicine to patients. Just one of every 10 therapies that enters human clinical trials makes it to the pharmacy. And science moves slowly: In the nearly 20 years since the human genome was sequenced, researchers have found treatments for a tiny fraction of the approximately 7,000 known rare diseases.Further, there are approximately 20,000 genes that can malfunction in at least 100,000 ways, and millions of possible interactions between the resultant proteins. It’s impossible for drug hunters to probe all of those combinations by hand.“If we want to understand the other 97 percent of human biology, we will have to acknowledge it is too complex for humans,” said Chris Gibson, the co-founder and Chief Executive Officer of Recursion Pharmaceuticals, a Salt Lake City-based startup that uses machine learning to hunt for new therapies.Companies like Recursion are rapidly luring investors. Venture capitalists poured $1.08 billion into AI and machine-learning startups focused on drug discovery last year, according to data provider PitchBook, up from just $237 million in 2016, and have already put in $699 million more so far this year.  Recursion raised $121 million in its latest financing round, the company said on Monday, from investors including Intermountain Ventures and the Regents of the University of Minnesota. It has a valuation of $646 million, according to PitchBook. “It is a very ambitious company. They are thinking in terms of radically changing the industry,” said Marina Record, an investment manager at Baillie Gifford & Co. in Scotland, which led the funding round.Established drugmakers are racing to ally with companies doing similar work.In April, Gilead Sciences Inc. agreed to a deal with Insitro, a startup led by the former Stanford University machine-learning expert Daphne Koller, to find ways to treat liver disease NASH. AstraZeneca Plc the same month linked up with U.K.-based BenevolentAI to identify treatments for kidney disease and lung fibrosis. In June, GlaxoSmithKline Plc partnered with gene-editing pioneers at the University of California in a $67 million target-hunting collaboration that will use AI.“Where else would you accept a 1-in-10 success rate?” said GlaxoSmithKline senior vice president Tony Wood, who heads medicinal science and technology for the British pharmaceutical giant. “If we could double that to 20% it would be phenomenal.”  Machine-learning methods “are going to be critical” to drug discovery, said Juan Alvarez, an associate vice president for computational chemistry at Merck & Co. The giant drugmaker is developing AI tools to help its chemists accelerate the laborious process of crafting chemicals to block aberrant proteins. Early machine-learning efforts have already contributed to drugs in human testing, while the first drugs based on more advanced neural-network methods could hit trials in several years, Alvarez said.Artificial intelligence could be used to scan millions of high-resolution cellular images—more than humans could ever process on their own—to identify therapies that could make diseased cells healthier in unexpected ways.At Recursion, one of the earliest startups to use such methods, each week robots apply thousands of potential drugs to various types of diseased cells, in 400,000 to 500,000 miniature experiments that generate 5 to 10 million cellular images. Machine-learning algorithms then scan the images, searching for compounds that disrupt disease without harming healthy cells.  The initial algorithms were coded by hand to interpret basic cellular features, but Recursion is increasingly using neural-network methods that directly interpret the images and may spot patterns human programmers wouldn't have looked for. Computer scientists work in tandem with biologists in the laboratory to refine the leads.  The company, which has agreed to rare-disease deals with Takeda Pharmaceutical Co. Ltd. and Sanofi, generated more than 2.5 petabytes of data in the past few years, a total that exceeds roughly the bandwidth of all Hollywood feature films. What the company is doing “just wasn't feasible six, or seven, or eight years ago,” said Gibson, its founder. Gibson first turned to machine learning as a graduate student at the University of Utah searching for treatments for cerebral cavernous malformation, which causes abnormal clumps of leaky blood vessels in the brain. The disorder affects about 1 in 500 people, according to the Angioma Alliance, and while often silent, can lead to seizures, speech or vision difficulties, and devastating brain hemorrhages. About a quarter of patients have a genetic form of the illness that is more likely to cause multiple malformations. Even though the three genes that cause it are known, there are no pharmaceutical treatments. One drug Gibson tested at the University of Utah based on the prevailing understanding of the disease made its symptoms worse in animals.Frustrated, Gibson and his colleagues used open-source machine-learning software for scanning cellular images to probe the effects of 2,100 compounds, searching for ones that improved the appearance and function of blood vessel cells that carried the bad genes. The algorithms pointed to an unexpected chemical that reduced leaky blood vessels in animal tests by 50 percent. That drug, set to enter second-stage human trials next year, led to the founding of Recursion.Other parts of Alphabet, as well as the AI research unit of social-media giant Facebook Inc., which quietly released a paper using deep learning to analyze 250 million protein sequences in April, are creeping into pharmaceutical-company turf. This spring, AI researchers at Google unveiled a neural network that can predict the function of a protein from its sequence of amino acids, which can help biologists understand what a newly discovered protein does. AI proponents say that nobody is talking about taking human researchers out of the equation. The goal is “augmenting and enhancing the decision-making capacity of scientists,” said Jackie Hunter, a former GlaxoSmithKline research executive who now leads clinical programs at BenevolentAI. In the short run, it’s more likely that AI-based simulations will be used to game out whether prospective drugs will be effective before going to a full-on clinical trial.An aerospace company “won’t build and fly a plane without building it on the computer first and simulating it under many conditions,” said Colin Hill of GNS Healthcare, a startup using AI to model disease, whose investors include Amgen Inc. In the future, drugmakers won’t begin clinical trials without a virtual dry run, Hill said.Still, the surprise that unfolded in Mexico has increased the tempo. DeepMind “basically beat everyone by a sizeable margin” said AlQuraishi, the Harvard researcher.  If drugmakers don’t take the threat seriously, he said, they could be left in the dust.  To contact the author of this story: Robert Langreth in New York at rlangreth@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters6 days ago

    UPDATE 1-AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes

    British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare-type of the condition. The company said the regulator issued a complete response letter, declining its application for using the drug in patients with Type-1 diabetes where insulin alone has not been able to control blood sugar levels. Farxiga is already approved in the United States for use in Type-2 diabetes, the more common form of the condition.

  • Financial Times7 days ago

    GSK to appoint Jonathan Symonds as chairman

    GlaxoSmithKline is to hire Jonathan Symonds, a former finance director at rival drugmakers AstraZeneca and Novartis, as its new chairman to oversee a break-up of the UK pharmaceuticals group. The appointment of Mr Symonds, who is currently deputy group chairman of HSBC, will end a six-month search for a replacement for Sir Philip Hampton, who has been non-executive chairman of GSK since 2015. Mr Symonds has extensive experience of the pharmaceutical industry.

  • Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
    Yahoo Finance9 days ago

    Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump

    Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.

  • TheStreet.com9 days ago

    AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

    Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

  • Here's how you can find the prices of some popular drugs online
    Yahoo Finance10 days ago

    Here's how you can find the prices of some popular drugs online

    A federal district court judge on Monday stopped the Trump administration from requiring drug makers to disclose drug wholesale prices in TV ads. But consumers can still find drug prices.

  • Financial Times10 days ago

    AstraZeneca takes lessons from fast food to serve China

    As growth slows for drug companies in China on government efforts to cut prices, AstraZeneca hopes it can draw lessons from an unlikely source: fast-food chains. Branded drugs with expired patents have remained top sellers in China’s $137bn pharmaceutical market even as sales have collapsed elsewhere because of competition from cheaper generic alternatives. One major reason is that patients have doubted the quality of generics made by Chinese companies.

  • GSK hikes price of subsidiary Tesaro's ovarian cancer drug
    American City Business Journals19 days ago

    GSK hikes price of subsidiary Tesaro's ovarian cancer drug

    Drug giant GlaxoSmithKline raised the price of cancer drug Zejula by 5 percent this week, bringing the cost for a 30-day supply of 100 milligram Zejula tablets from $6,567 to $6,913.

  • What Did AstraZeneca PLC's (LON:AZN) CEO Take Home Last Year?
    Simply Wall St.21 days ago

    What Did AstraZeneca PLC's (LON:AZN) CEO Take Home Last Year?

    Pascal Soriot has been the CEO of AstraZeneca PLC (LON:AZN) since 2012. This report will, first, examine the CEO...

  • How Much Are AstraZeneca PLC (LON:AZN) Insiders Spending On Buying Shares?
    Simply Wall St.21 days ago

    How Much Are AstraZeneca PLC (LON:AZN) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
    Market Realistlast month

    How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

    On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.

  • AstraZeneca’s Lynparza Continues to Dominate
    Market Realistlast month

    AstraZeneca’s Lynparza Continues to Dominate

    In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.

  • AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
    Reuterslast month

    AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said. BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

  • Reuterslast month

    UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

  • Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
    Market Realistlast month

    Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

    AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.

  • How Are AstraZeneca’s Revenues Trending in 2019?
    Market Realistlast month

    How Are AstraZeneca’s Revenues Trending in 2019?

    On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.

  • What Analysts Recommend for Merck and AstraZeneca in June
    Market Realistlast month

    What Analysts Recommend for Merck and AstraZeneca in June

    Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.

  • Is AstraZeneca plc  (AZN) A Good Stock To Buy?
    Insider Monkeylast month

    Is AstraZeneca plc (AZN) A Good Stock To Buy?

    At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]

  • AstraZeneca weighs in on Trump's attack on big drug
    Yahoo Finance Video9 days ago

    AstraZeneca weighs in on Trump's attack on big drug

    AstraZeneca EVP Ruud Dobber speaks with Yahoo Finance's Alexis Christoforous and Brian Sozzi about the future of pharmaceuticals and President Trump's push to lower drug prices.